Jinfang Zhang

18PUBLICATIONS
78CO-AUTHORS
Innate immunityMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursChemical engineering design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Sep 02, 2026
RAS P21 Protein Activator 3 finetunes Type I immunity by limiting HCK-mediated STAT4 phosphorylation.

|Jan 08, 2026
CDK10 suppresses nucleic acid sensors-mediated antitumor immunity.

Gaoshan Xu, Fusheng Guo, Chuan He

|Nov 12, 2025
Targeted destruction of VISTA boosts anti-tumor immunotherapy.

Li Chen, Xia Bu, Yishuang Sun

|Nov 12, 2025
Destruction of VISTA by TRIM25 ablation in T cells potentiates cancer immunotherapy.

Yishuang Sun, Zijian Zhang, Haiou Li

|Sep 05, 2025
ChREBP-Mediated Choline Deprivation and Chemokine Secretion Shape Tumor-Associated Macrophages to Promote Immune Evasion.

Jianhong Zhao, Baoxiang Chen, Yanrong Deng

|May 16, 2025
USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity.

Panpan Dai, Yishuang Sun, Zhengrong Huang

Pageof 3

Frequent Collaborators

12 joint publications

Wenyi Wei

6 joint publications

Jing Liu

6 joint publications

Gordon J Freeman

4 joint publications

Conghua Xie